1,0
27 mag 2022
Ex dipendente, più di 5 anni
Vancouver, BC
Consiglia
Gradimento del CEO
Pronostico commerciale
Vantaggi
Zanidatamab is an excellent asset
Svantaggi
- Talented & experienced group of scientists that developed Zanidatamab are no longer at Zymeworks - Senior Scientific leadership does not have the necessary drug development experience - Success of pipeline projects doesn't matter, company is treading water to get to a sale - CEO has no history developing medicine or building companies. His history is dominated by breaking apart and selling assets. - Former CFO, at least partly responsible for the cratering of the company, is allowed to remain and transition to COO. - Company still talks about its values as though they determine corporate behavior